Safeguarding Newborn Dried Blood Spot Screening in Viet Nam: Specimen Quality, Screening Cutoff Validation and Diagnostic Confirmation
DIAGNOSTIC SAFETY & RISK MANAGEMENTMEASUREMENT, LEARNING & IMPROVEMENT
11/6/202624 min read


Safeguarding Newborn Dried Blood Spot Screening in Viet Nam: Specimen Quality, Screening Cutoff Validation and Diagnostic Confirmation
A newborn may appear healthy during the first days of life while having a congenital disorder that has not yet produced recognizable symptoms. For some conditions, identifying the disease before symptoms develop can make a substantial difference to the child's health and long-term development.
This is the value of newborn screening. Yet its benefits depend on much more than the availability of a laboratory test.
A poorly collected blood spot may produce an unreliable measurement. A screening cutoff that does not adequately account for the infant's characteristics may lead to unnecessary referrals or missed disease. Even when an infant is correctly identified as being at increased risk, the opportunity for early intervention may be lost if the family cannot be contacted or diagnostic confirmation is delayed.
An in-range result presents a different concern. It may provide reassurance, but it cannot establish with certainty that every disorder included in the screening panel has been excluded.
Newborn dried blood spot (DBS) screening is therefore best understood as a connected process involving specimen collection, analytical performance, screening decision rules, result communication, and access to appropriate diagnostic services.
For healthcare organizations in Viet Nam, improving reliability means examining how these elements work together. A technically advanced laboratory cannot fully compensate for unsuitable specimens, inappropriate decision thresholds, or high-risk results that never receive appropriate follow-up.
Newborn Screening Identifies Risk, Not a Definitive Diagnosis
Newborn DBS screening uses small quantities of blood collected on specialized filter paper to measure biochemical, enzymatic, or molecular markers associated with selected congenital disorders.
Depending on the screening program, these may include congenital hypothyroidism, congenital adrenal hyperplasia, glucose-6-phosphate dehydrogenase (G6PD) deficiency, inherited metabolic disorders, and other conditions for which suitable screening methods are available.
Many affected infants have no obvious clinical abnormalities immediately after birth. Screening can identify those who require further evaluation before serious complications become apparent.
However, screening and diagnosis serve different purposes.
An out-of-range result indicates that the infant meets the program's criteria for additional assessment. It does not necessarily establish that the suspected disorder is present. An in-range result means that the measured markers did not meet the applicable criteria for further investigation at the time of testing. It does not guarantee that the infant is unaffected.
These distinctions are particularly important when screening for rare conditions. Even a well-performing screening method may identify some unaffected infants as being at increased risk.
The challenge is to detect affected infants as reliably as possible while limiting avoidable false-positive results, unnecessary investigations, and anxiety for families.
Achieving this balance requires more than analytical accuracy. It also requires an appropriate screening strategy, reliable interpretation, and a clinical pathway capable of resolving important findings.
Specimen Quality Begins Before the Laboratory Receives the Sample
The reliability of a newborn screening result begins with the specimen.
Unlike conventional liquid blood testing, DBS screening uses blood absorbed into specialized filter paper. A defined portion of the dried spot is subsequently removed for analysis.
This method facilitates collection and transportation, particularly when maternity facilities send specimens to centralized screening laboratories.
However, the amount and distribution of blood absorbed into the paper can influence analytical measurements.
A specimen may be unsuitable if the filter paper is inadequately saturated, if successive drops of blood are layered over one another, or if the spot is uneven, contaminated, damaged, or improperly dried.
Excessive heat, moisture, unsuitable storage, and delays in transportation may also compromise specimen integrity. The effects vary according to the biomarker and analytical method.
These problems can alter the amount of material analyzed, affect analyte stability, or prevent a valid result from being obtained. Depending on the circumstances, they may contribute to false-positive findings, false-negative findings, or the need for recollection.
The Clinical and Laboratory Standards Institute (CLSI) addresses these risks in NBS01: Dried Blood Spot Specimen Collection for Newborn Screening, seventh edition, published in 2021.
The standard provides guidance on collection materials, specimen application, handling, drying, storage, transportation, and the identification of unacceptable specimens.
For healthcare organizations, the practical implication is that obtaining blood does not necessarily mean obtaining a suitable screening specimen.
Laboratories should establish clear specimen acceptance and rejection criteria. Maternity facilities and other collecting services need appropriate training, reliable collection materials, and feedback when specimen quality problems occur.
Where recollection is necessary, responsibility should be established for contacting the family and obtaining another suitable sample within an appropriate timeframe.
A rejected specimen must not be treated as an in-range screening result. Nor should a request for recollection be regarded as completed screening.
The process should allow healthcare professionals to determine whether the infant ultimately received a valid screening result.
Collection Timing Can Change the Meaning of the Result
Newborn physiology changes rapidly during the first days after birth. Hormone concentrations, metabolic activity, feeding patterns, and physiological adaptation can influence the biomarkers used in screening.
Consequently, the timing of specimen collection may affect screening performance even when the collection technique and analytical method are technically correct.
International newborn screening programs use different collection windows according to the disorders being screened, available methods, and healthcare delivery arrangements.
In Viet Nam, Decision No. 2818/QD-BYT, issued by the Ministry of Health on September 7, 2026, provides updated professional technical guidance on prenatal and newborn screening, diagnosis, and treatment.
For DBS screening, the guidance identifies newborns aged 24 to 72 hours as the principal screening group, with approximately 48 hours after birth indicated as the preferred collection time.
When an infant leaves a maternity facility before 24 hours of age, the guidance calls for blood collection before discharge.
Early collection helps reduce the risk of a missed screening opportunity. Nevertheless, biomarkers measured before the usual collection window may require additional interpretation, and some infants may need another specimen under the relevant disease-specific protocol.
This should not be interpreted as a universal requirement to repeat every DBS examination after early discharge.
Blood transfusion presents another challenge. The Vietnamese guidance recommends collecting a screening specimen before transfusion when an infant requires blood transfusion.
Transfused blood may affect certain screening measurements, particularly tests involving red blood cell enzymes or other markers influenced by donor blood.
Where screening occurs after transfusion, the laboratory and clinical teams should document the circumstances, assess possible interference, and determine whether additional testing is necessary under the applicable protocol.
The reliability of a screening result therefore depends partly on information that may not be visible in the laboratory measurement itself.
Age at collection, gestational age, birth weight, transfusion history, and relevant treatment exposures can all influence interpretation. Accurate documentation of these details is an important part of the screening process.
Premature and Critically Ill Newborns Require Particular Attention
Premature infants, infants with low birth weight, and newborns receiving intensive care may have screening profiles that differ substantially from those of healthy term newborns.
Immaturity of endocrine and metabolic systems can influence biomarker concentrations. Parenteral nutrition, medication exposure, transfusion, severe illness, and other interventions may also affect screening results.
These circumstances create different risks.
Some affected infants may be missed if screening algorithms do not adequately account for their physiological characteristics. Others may receive out-of-range results despite not having the targeted disorder.
CLSI NBS03, Newborn Screening for Preterm, Low Birth Weight, and Sick Newborns, second edition, published in 2019, provides guidance on screening approaches and additional specimen collection for these populations.
However, repeat-screening requirements are not identical for every condition.
The Vietnamese Ministry of Health's 2026 guidance includes specific provisions for repeat screening for congenital hypothyroidism.
For infants born before 32 weeks of gestation, it specifies a second screening specimen at 28 days of age. For infants affected by twin-to-twin transfusion and those with Down syndrome, it specifies repeat screening at two to four weeks after birth.
These are disease-specific provisions. They should not automatically be extended to every disorder included in a newborn DBS screening panel.
Healthcare organizations need a process for identifying infants whose screening pathway differs from routine newborn care.
For these infants, a specimen card containing complete and accurate clinical information is especially important. Missing gestational age, birth weight, collection time, or transfusion history may affect whether the result can be interpreted correctly.
These details are not merely administrative fields. They can influence the clinical meaning of the screening measurement.
Screening Cutoffs Are Clinical Decision Rules, Not Just Laboratory Numbers
A screening cutoff is a predefined value or decision criterion used to determine whether a result falls within the expected screening range or requires additional evaluation.
The process may appear straightforward. The laboratory measures a biomarker, compares the value with a threshold, and classifies the result.
In practice, selecting an appropriate cutoff involves balancing the possibility of missing affected infants against the consequences of referring unaffected infants for further investigation.
For biomarkers in which elevated concentrations indicate increased risk, lowering the cutoff may increase sensitivity but also produce more false-positive classifications. Raising it may reduce unnecessary referrals while increasing the possibility that infants with less pronounced abnormalities will be missed.
For biomarkers in which low concentrations indicate risk, the direction of these effects may differ.
There is no single approach that is optimal for every disorder.
The appropriate decision threshold depends on the biological characteristics of the condition, analytical method, specimen characteristics, screened population, and consequences of delayed detection.
This is why screening cutoffs should not automatically be copied from another laboratory or country.
Differences in assay calibration, analytical platforms, age at collection, population characteristics, and biomarker distributions may affect performance.
Where a laboratory develops its own cutoff, evaluation should consider analytical performance, representative population data, known affected cases where available, and relevant external evidence.
Where an established cutoff is adopted, the laboratory should verify that it is suitable for the analytical method and population in which it will be used.
Developing a new cutoff and verifying an externally established cutoff are related but different activities. Their evidence requirements and study designs may not be identical.
Screening decision rules may also involve several biomarkers, ratios, age-related adjustments, or additional testing steps.
A cutoff that performs acceptably within one screening algorithm may not provide equivalent performance when used independently.
The quality of the decision rule therefore matters as much as the numerical value itself.
Congenital Adrenal Hyperplasia Illustrates the Importance of Cutoff Validation
Congenital adrenal hyperplasia provides a useful example of how screening performance depends on biological variation and analytical specificity.
Many newborn screening programs measure 17-hydroxyprogesterone (17-OHP) as an initial marker for classic congenital adrenal hyperplasia associated with 21-hydroxylase deficiency.
However, 17-OHP concentrations can also be elevated in premature infants or those experiencing physiological stress, even when the targeted disorder is absent.
A single cutoff applied without sufficient consideration of these factors may result in substantial numbers of false-positive findings.
CLSI NBS11, Newborn Screening for Congenital Adrenal Hyperplasia, published in August 2025, addresses disease-specific screening strategies and factors affecting analytical interpretation.
A study by Gaudl and colleagues, published in Clinica Chimica Acta in January 2026, provides a recent example of how analytical methods and cutoff selection can influence screening performance.
The researchers evaluated a liquid chromatography-based triple-stage mass spectrometric method, LC-MS/MS/MS, for measuring 17-OHP in residual dried blood spot specimens.
The study included 1,730 selected specimens and evaluated cutoffs adjusted for gestational age and birth weight.
Within this dataset, the combination of the more specific analytical method and maturity-dependent cutoffs reduced false-positive classifications from 731 under the comparison immunoassay strategy to 15, while identifying all seven confirmed congenital adrenal hyperplasia cases represented in the evaluation.
The findings illustrate how improved analytical specificity and appropriately selected decision thresholds can reduce unnecessary referrals.
However, the study used selected residual specimens rather than an unselected national birth cohort. The small number of confirmed affected cases also limits conclusions about sensitivity.
Its findings should not be interpreted as evidence that the same numerical cutoffs would perform identically in every screening population.
For laboratories in Viet Nam, the study supports the importance of method verification and appropriate cutoff evaluation. It does not justify adopting the reported thresholds without local assessment.
Other congenital disorders present different challenges.
For congenital hypothyroidism, screening timing and neonatal thyroid physiology affect thyroid-stimulating hormone measurements. The choice of TSH-based, T4-based, or combined strategies also influences which presentations may be detected.
For G6PD deficiency, interpretation depends on enzyme activity, analytical method, and relevant biological factors.
For inherited metabolic disorders, screening algorithms may use combinations of metabolites and ratios measured through tandem mass spectrometry.
Each disorder requires an approach appropriate to its biology, analytical limitations, and the clinical consequences of an incorrect classification.
Second-Tier Screening Is Not Diagnostic Confirmation
Modern newborn screening programs may use additional tests to improve the specificity of an initial result.
These are commonly described as second-tier screening tests.
A second-tier assay may measure additional biomarkers or use a more specific analytical method to help determine whether an initial out-of-range result is likely to represent the targeted disorder.
For example, steroid profiling using mass spectrometry may help clarify an elevated 17-OHP result. Other second-tier strategies may improve classification for selected metabolic disorders.
These approaches can reduce unnecessary referrals while preserving the ability to identify infants at increased risk.
However, second-tier screening should not automatically be regarded as diagnostic confirmation.
A more specific screening result may provide stronger evidence of risk, but it does not necessarily establish a definitive diagnosis.
Confirmation may require a different specimen, targeted biochemical investigations, quantitative enzyme testing, molecular analysis, clinical assessment, or a combination of these methods.
The appropriate pathway depends on the suspected condition.
This distinction is particularly important when laboratories introduce sophisticated analytical platforms. Greater analytical capability can improve screening, but it does not eliminate the need for diagnostic services.
An infant with a high-risk screening result still requires appropriate clinical assessment under the relevant professional guidance.
The objective is not simply to produce increasingly detailed screening classifications. It is to ensure that the information leads to a clinically meaningful determination and, where necessary, timely care.
Laboratory Quality Control Cannot Establish Clinical Screening Performance Alone
Routine laboratory quality control is essential for newborn screening, but it cannot answer every question about program reliability.
A laboratory may demonstrate consistent measurements while using an inappropriate screening cutoff. Conversely, a well-designed cutoff cannot compensate for unstable analytical performance.
Internal quality control helps monitor measurement stability and precision. External quality assessment and proficiency testing provide additional evidence about analytical performance.
The United States Centers for Disease Control and Prevention operates the Newborn Screening Quality Assurance Program (NSQAP), which supports screening laboratories through reference materials, quality control, proficiency testing, and technical assistance.
These activities help laboratories identify technical weaknesses and evaluate the reliability of their analytical methods.
However, acceptable proficiency testing does not independently establish that a screening algorithm has appropriate clinical sensitivity or specificity.
Clinical screening performance also requires information about confirmed disease, false-positive results, and affected infants who were not detected.
This evaluation can be difficult for rare disorders. A laboratory may have only a small number of confirmed cases available for validation, making estimates of sensitivity uncertain.
Claims that a screening strategy is completely sensitive should therefore be avoided when evidence is limited.
International collaboration, appropriate validation studies, and systematic assessment of confirmed cases can help strengthen confidence in screening performance.
Analytical quality control and clinical performance evaluation should be viewed as complementary responsibilities.
Screening Cutoffs Must Remain Under Review
A screening cutoff should not be regarded as permanently reliable simply because it performed acceptably during initial validation.
Analytical conditions and screening populations can change over time.
A new laboratory platform, reagent lot, calibration procedure, specimen collection arrangement, or reporting algorithm may affect measured results.
Changes in the screened population may also influence biomarker distributions.
For example, an increase in the proportion of premature infants could change the frequency of out-of-range 17-OHP results without any deliberate modification to the cutoff.
A laboratory observing such a shift should investigate its cause before changing the decision threshold.
Relevant information includes analytical quality control results, specimen quality, collection timing, biomarker distributions, recall rates, and outcomes of confirmatory testing.
Reducing unnecessary referrals is desirable, but a cutoff change should not create an unacceptable risk of missing affected infants.
Where sufficient evidence is available, proposed changes should be evaluated using appropriate historical data, confirmed affected cases, and relevant external information.
The laboratory should also preserve information about which assay version, screening algorithm, and cutoff were used for each result.
Without this information, later evaluation of false-positive or false-negative cases may become difficult.
Cutoff revisions should be documented, professionally authorized, and monitored after implementation.
A screening threshold is therefore not simply a number stored in laboratory software. It is an important clinical decision rule whose performance should remain under review.
What Recent Vietnamese Studies Tell Us
Two studies published in 2026 provide useful evidence about newborn screening performance in Viet Nam.
The first, published in the Hue Journal of Medicine and Pharmacy in March 2026, examined G6PD deficiency screening using dried blood spot specimens from newborns in central Viet Nam and the Central Highlands.
The researchers analyzed 7,532 newborns screened between January 2024 and February 2025.
The proportion classified as high risk for G6PD deficiency was 3.6%. Among infants with high-risk screening findings, 19.56% were recorded as having undergone confirmatory diagnostic testing.
The study highlights an important concern about the visibility and completion of follow-up after screening.
However, its findings should be interpreted within the available data. The reported proportion should not be presented as the national diagnostic follow-up rate or as proof that every infant without documented confirmation received no further assessment elsewhere.
The second study, published in the Journal of the ASEAN Federation of Endocrine Societies in April 2026, evaluated a two-step TSH screening strategy for congenital hypothyroidism in Ninh Binh Province.
The retrospective study included 11,306 newborns screened between January 2019 and December 2020.
The investigators reported improved specificity and positive predictive value after introducing a second screening step. Specificity increased from 97.64% at the first screening stage to 99.81% at the second, while positive predictive value increased from 1.11% to 11.54%.
Four cases of congenital hypothyroidism were confirmed, including one false-negative case identified clinically after screening.
The reported sensitivity of 75% was therefore based on very few affected infants. This limits confidence in how precisely the estimate represents performance in a larger population.
The results support the potential benefit of a two-step screening strategy for reducing unnecessary referrals, while illustrating why the possibility of missed disease must remain part of program evaluation.
These studies concern different disorders and use different screening methods. They cannot be combined into a single estimate of newborn screening quality across Viet Nam.
Nevertheless, both reinforce an important principle: laboratory screening performance and the ability to establish diagnostic outcomes must be evaluated together.
High-Risk Results Require Timely Clinical Assessment
Some newborn screening results suggest conditions in which significant complications can develop rapidly.
For selected metabolic and endocrine disorders, delays in assessment or treatment may have serious consequences.
The potential benefit of screening can therefore be substantially reduced if a high-risk result is reported but appropriate clinical evaluation does not follow.
CLSI NBS02, Newborn Screening Follow-up and Education, third edition, published in 2023, addresses communication, education, and follow-up throughout newborn screening programs.
It recognizes that laboratory detection is only one element of a wider system involving diagnostic assessment, intervention, and evaluation.
In Viet Nam, Decision No. 2818/QD-BYT provides for prompt notification and counseling of parents or legal guardians when a high-risk newborn screening result is identified.
The guidance also addresses coordination with the specimen-collecting facility and relevant management authority.
Infants with high-risk findings should be directed to healthcare services with the professional capability and authorization required for diagnostic assessment.
Clinical urgency differs between disorders.
Some results require urgent specialist evaluation, and appropriate management may need to begin while confirmatory investigations are underway. Other findings may permit a planned sequence of further tests.
The specific response should reflect the suspected disorder, the infant's condition, and applicable professional guidance.
A single follow-up interval cannot adequately address every high-risk newborn screening result.
Communication with families is important, but notification or referral should not automatically be regarded as completed diagnostic assessment.
The screening and diagnostic services need workable arrangements for establishing whether the infant received the necessary evaluation.
Diagnostic Confirmation Must Resolve the Clinical Question
Confirmatory testing is intended to determine whether an infant identified as being at increased risk actually has the suspected disorder.
The appropriate investigations differ by condition.
For congenital hypothyroidism, assessment generally includes serum thyroid-stimulating hormone and free thyroxine measurements, interpreted according to the infant's age and clinical circumstances.
For congenital adrenal hyperplasia, further evaluation may include steroid measurements, electrolyte assessment, and additional biochemical or molecular investigations when indicated.
For G6PD deficiency, appropriately validated quantitative enzyme activity testing may be necessary.
For inherited metabolic disorders, confirmation may require targeted biochemical testing, enzyme studies, molecular analysis, or other specialized investigations.
These examples do not constitute a universal diagnostic protocol.
An additional dried blood spot specimen may help resolve a borderline or technically uncertain screening result in selected circumstances.
However, repeating a screening test is not necessarily equivalent to definitive diagnosis.
The Vietnamese Ministry of Health's 2026 guidance describes confirmatory approaches for several conditions included in DBS screening and establishes the role of appropriately capable healthcare facilities in diagnostic assessment.
A dependable screening program should know where the relevant diagnostic services are available and how responsibility is coordinated when an infant is referred.
The outcome may be confirmation of disease, exclusion of the suspected condition, or an indeterminate result requiring further assessment.
These outcomes should be documented appropriately.
Families should not be left with unresolved high-risk screening findings simply because an initial referral was issued.
False-Positive and False-Negative Results Require Different Responses
False-positive and false-negative findings have different implications for newborn screening quality.
A false-positive result occurs when an infant is classified as being at increased risk, but subsequent assessment does not confirm the targeted disorder.
These findings can create anxiety for families and increase demand for specialist assessment.
However, a false-positive result does not necessarily indicate that the laboratory performed the test incorrectly.
It may reflect the screening strategy's emphasis on sensitivity, physiological variation, or other characteristics influencing biomarker measurements.
Some false positives are an expected consequence of screening for rare but potentially serious conditions.
The objective is to reduce avoidable false positives without compromising the detection of affected infants.
False negatives present a different concern.
A false-negative result occurs when an infant with the targeted disorder receives an in-range screening result.
The condition may only become apparent after symptoms develop or additional clinical investigations are performed.
An in-range result should therefore not override clinical assessment when a child subsequently develops symptoms or findings suggestive of a screened disorder.
Healthcare organizations should have appropriate arrangements for examining confirmed cases that were not identified during screening.
Such review may reveal limitations in specimen quality, analytical performance, cutoff selection, disease phenotype, or other aspects of the screening process.
A subsequent diagnosis does not automatically establish that a preventable laboratory error occurred.
The purpose of review is to understand what happened, evaluate whether the screening strategy performed as intended, and identify opportunities for improvement.
Measuring Reliability Across the Entire Screening Process
The number of newborns screened is an important operational measure, but it does not establish whether a screening program is reliable.
A program may process large numbers of specimens while experiencing collection problems, delayed reporting, incomplete diagnostic follow-up, or missed cases.
Meaningful assessment should begin with the eligible newborn population.
The organization needs to determine which infants received a valid screening result and which did not complete the intended process.
This requires distinguishing infants who were not screened, those whose specimens were rejected, and those whose screening remained incomplete.
Specimen quality can be assessed through rejection rates, reasons for rejection, and successful recollection.
However, a low rejection rate should not automatically be interpreted as good performance if unsuitable specimens are being accepted.
Timeliness also matters.
Relevant intervals include birth to collection, collection to laboratory receipt, receipt to screening result, and high-risk result to communication with the family or responsible clinician.
For infants requiring further evaluation, the time from a high-risk finding to appropriate diagnostic assessment may be especially important.
The relevant timeframe should reflect disease-specific urgency.
Screening cutoff performance requires additional indicators.
Out-of-range rates, recall rates, positive predictive value, and confirmed false-positive findings can provide useful information.
Where reliable information about affected infants is available, sensitivity and false-negative rates can help evaluate the screening strategy.
Positive predictive value describes the proportion of screen-positive infants who are subsequently confirmed to have the targeted disorder.
It depends on the test's performance and the prevalence of the disease in the screened population.
A program screening for a very rare disorder may have a relatively low positive predictive value despite reasonably strong analytical performance.
Incomplete ascertainment of confirmatory outcomes can also make estimates misleading.
For these reasons, performance indicators should not be compared across diseases, laboratories, or populations without considering their definitions and underlying characteristics.
Each indicator should have a clear numerator, denominator, data source, and review method.
The most useful measurement system identifies where screening reliability may be compromised and whether clinically important results lead to appropriate care.
Applying Viet Nam's Updated Legal and Professional Framework
Viet Nam updated its legal and professional framework for prenatal and newborn screening during 2026.
The Law on Population No. 113/2025/QH15, adopted on December 10, 2025, took effect on July 1, 2026.
Article 21 encourages prenatal and newborn screening for congenital conditions according to the disease lists issued by the Ministry of Health.
Circular No. 12/2026/TT-BYT, issued on May 15, 2026, establishes the lists of congenital conditions recommended for prenatal and newborn screening.
The newborn screening framework distinguishes disorders assessed using dried blood spots from conditions screened by other methods, including hearing screening and screening for certain congenital cardiac abnormalities.
These modalities have different technical requirements and should not be treated as interchangeable.
The inclusion of a condition in the recommended screening list does not automatically mean that every healthcare facility is required to screen every newborn for every listed disorder.
Organizations need to consider their authorized activities, available methods, professional capacity, and applicable requirements.
Decision No. 2818/QD-BYT, issued on September 7, 2026, provides updated professional technical guidance on prenatal and newborn screening, diagnosis, and treatment.
It replaced Decision No. 1807/QD-BYT dated April 21, 2020.
For DBS screening, the guidance addresses specimen collection, preservation, transportation, analytical methods, result communication, and subsequent diagnostic assessment.
It specifies natural drying of DBS cards at room temperature for at least four hours, protection against contamination and damaging environmental conditions, and recommends dispatch for screening within 24 hours after collection.
The guidance also emphasizes collecting accurate identification and contact information so that families can be reached when further assessment is necessary.
These provisions offer an important national professional foundation for improving the reliability of newborn screening services.
International CLSI standards can support technical quality, but their recommendations should be considered alongside applicable Vietnamese requirements rather than automatically replacing them.
Laboratory Quality and Professional Accountability
Newborn screening laboratories operate within broader requirements governing medical laboratory competence, quality management, and healthcare services.
TCVN ISO 15189:2025, Medical Laboratories: Requirements for Quality and Competence, is the Vietnamese national standard technically identical to ISO 15189:2022.
It provides a framework for laboratory competence, quality management, risk management, and the reliability of examination results.
However, the existence of a national standard does not automatically require every medical laboratory in Viet Nam to obtain ISO 15189 accreditation.
Applicable obligations depend on relevant law, the laboratory's activities, and any accreditation or contractual commitments.
Circular No. 01/2013/TT-BYT on laboratory quality management in healthcare facilities, as amended by relevant subsequent instruments including Circular No. 25/2026/TT-BYT, is also relevant to laboratory governance.
Healthcare organizations must additionally consider the Law on Medical Examination and Treatment No. 15/2023/QH15 and its applicable implementing regulations.
Responsibilities within a newborn screening program extend across several services.
Maternity and newborn care providers contribute to identifying infants for screening, collecting appropriate specimens, and documenting necessary clinical information.
Screening laboratories are responsible for the quality and interpretation of examinations within their authorized activities.
Pediatric and specialist services provide diagnostic assessment and clinical management.
Program coordinators and healthcare leadership help establish the arrangements needed for these services to work together.
The availability of an advanced screening platform does not eliminate these responsibilities.
A reliable program should be able to demonstrate that its analytical methods, staff competence, decision rules, specimen management, and access to diagnostic services are appropriate for the disorders being screened.
Family Communication, Privacy, and Residual Specimens
Parents and legal guardians should understand that newborn screening identifies possible health risks before symptoms develop. It does not necessarily establish a diagnosis.
This distinction becomes particularly important when a high-risk result is reported.
Families may interpret an abnormal result as confirmation that their child has a serious condition.
Healthcare professionals should explain what the result indicates, what remains uncertain, and why further assessment is necessary.
Communication should avoid unnecessary alarm without minimizing the need for prompt care when a potentially serious finding has been identified.
Families should receive clear information about where further assessment can be obtained and whom to contact if difficulties arise.
Healthcare organizations should verify contact details and establish appropriate arrangements when a family cannot initially be reached.
Screening information may also include sensitive personal health and genetic data.
Viet Nam's Law on Personal Data Protection No. 91/2025/QH15 and Decree No. 356/2025/ND-CP took effect on January 1, 2026.
Healthcare organizations should assess applicable requirements concerning lawful data processing, confidentiality, authorized access, information security, record retention, and sharing of information between services.
The lawful basis for processing, consent requirements, and applicable exceptions depend on the purpose and circumstances of the activity.
Residual DBS specimens deserve particular attention.
Specimens originally collected for clinical screening may later be considered for research, method development, quality assessment, or other purposes.
These activities are not automatically legally or ethically interchangeable.
Secondary use should be assessed under applicable legal requirements, professional and ethical safeguards, and relevant authorization or consent arrangements.
A reliable screening program must preserve clinically necessary information while protecting the rights and interests of children and their families.
Turning Screening Performance Into Practical Improvement
Quality improvement becomes meaningful when performance information helps an organization identify and address a specific weakness.
Consider a screening laboratory that observes a sustained increase in out-of-range 17-OHP results.
An immediate response might be to raise the screening cutoff to reduce the number of referrals.
However, doing so without appropriate analysis could increase the risk of missing affected infants.
A more reliable approach would examine biomarker distributions, the characteristics of the infants screened, analytical performance, specimen collection conditions, and confirmatory outcomes.
The increase may reflect a higher proportion of premature infants, a change in the assay, specimen-related factors, or another source of variation.
The appropriate intervention may involve improved risk stratification, better analytical specificity, or changes to laboratory procedures rather than a simple numerical adjustment.
A different program may demonstrate stable analytical performance but repeated delays in contacting families after high-risk results.
In that situation, changing the cutoff would not address the principal safety concern.
Improvement may instead require more reliable contact information, clearer communication responsibilities, and better coordination with diagnostic services.
These examples illustrate why screening quality cannot be improved through a single intervention applied to every problem.
Specimen quality, analytical performance, cutoff validity, and diagnostic follow-up are different responsibilities, although failures in each can affect the same newborn.
For healthcare organizations in Viet Nam, the 2026 legal and professional updates provide an opportunity to strengthen quality assessment across maternity facilities, screening laboratories, and services responsible for diagnostic confirmation.
The priority should be to identify where the screening process is vulnerable, introduce changes appropriate to the identified problem, and determine whether those changes improve performance.
Strengthening Newborn Screening as Part of Diagnostic Excellence
Newborn dried blood spot screening can identify serious congenital disorders before clinical deterioration occurs, but its potential benefits depend on the reliability of the entire process.
The specimen must be suitable for analysis. Screening decision thresholds must be supported by appropriate evidence and remain suitable for the intended population. Results need to be interpreted in light of the analytical method and the infant's clinical circumstances.
When a high-risk finding is identified, the healthcare system must be able to provide appropriate diagnostic assessment and subsequent care.
International CLSI standards and disease-specific publications provide important technical foundations. Viet Nam's updated legal and professional framework offers national guidance for the organization of screening services.
For healthcare organizations, the opportunity is to connect these requirements with meaningful measurement and continuous improvement.
A screening program should not be judged only by the number of newborns tested or the number of abnormal results reported.
Its quality should also be assessed through specimen integrity, screening cutoff performance, the reliability of risk classification, and the completion of appropriate diagnostic evaluation.
Diagnostic excellence in newborn screening is not demonstrated simply by producing a laboratory result. It depends on whether the result is reliable enough for its intended purpose, whether its meaning is communicated accurately, and whether infants requiring further assessment receive appropriate care when it matters.
Selected References and Regulatory Sources
Clinical and Laboratory Standards Institute. CLSI NBS01: Dried Blood Spot Specimen Collection for Newborn Screening. Seventh edition. 2021.
Clinical and Laboratory Standards Institute. CLSI NBS02: Newborn Screening Follow-up and Education. Third edition. 2023.
Clinical and Laboratory Standards Institute. CLSI NBS03: Newborn Screening for Preterm, Low Birth Weight, and Sick Newborns. Second edition. 2019.
Clinical and Laboratory Standards Institute. CLSI NBS04: Newborn Screening by Tandem Mass Spectrometry. Second edition. 2017. Reaffirmed June 2022.
Clinical and Laboratory Standards Institute. CLSI NBS10: Newborn Screening for Congenital Hypothyroidism. First edition. 2024.
Clinical and Laboratory Standards Institute. CLSI NBS11: Newborn Screening for Congenital Adrenal Hyperplasia. First edition. 2025.
Clinical and Laboratory Standards Institute. CLSI NBS12: Newborn Screening for Galactosemias. First edition. May 19, 2026.
Gaudl A, Lehmicke L, Biemann R, Dittrich J, Ceglarek U. Enhancing Primary Newborn Screening Efficiency for Congenital Adrenal Hyperplasia With LC-MS/MS/MS. Clinica Chimica Acta. 2026;578:120482. DOI: 10.1016/j.cca.2025.120482.
Ha TMT, Tran TCV, Le TL, et al. Đánh giá kết quả sàng lọc thiếu enzyme glucose-6-phosphate dehydrogenase từ mẫu máu thấm khô của trẻ sơ sinh thuộc các tỉnh miền Trung và Tây Nguyên. Hue Journal of Medicine and Pharmacy. 2026;16(1):40–48. Article in Vietnamese. DOI: 10.34071/jmp.2026.1.612.
Nguyen HV, Tran KH, Nguyen BN, et al. Evaluating the Two-Step TSH Screening Protocol for Congenital Hypothyroidism: Prevalence and Diagnostic Accuracy in Ninh Binh, Vietnam. Journal of the ASEAN Federation of Endocrine Societies. 2026;41(1). DOI: 10.15605/jafes.041.01.5795.
Centers for Disease Control and Prevention. Newborn Screening Quality Assurance Program. U.S. Department of Health and Human Services.
Health Resources and Services Administration. Newborn Screening Results and Follow-Up. U.S. Department of Health and Human Services.
National Assembly of Viet Nam. Law on Population No. 113/2025/QH15. December 10, 2025. Effective July 1, 2026.
Ministry of Health of Viet Nam. Circular No. 12/2026/TT-BYT, Regulating the Lists of Congenital Conditions for Prenatal and Newborn Screening. May 15, 2026. Effective July 1, 2026.
Ministry of Health of Viet Nam. Decision No. 2818/QD-BYT, Promulgating Professional Technical Guidance on Prenatal and Newborn Screening, Diagnosis and Treatment. September 7, 2026. Replacing Decision No. 1807/QD-BYT of April 21, 2020.
International Organization for Standardization. ISO 15189:2022: Medical Laboratories: Requirements for Quality and Competence. 2022.
Ministry of Science and Technology of Viet Nam. TCVN ISO 15189:2025: Medical Laboratories: Requirements for Quality and Competence. Technically identical to ISO 15189:2022.
National Assembly of Viet Nam. Law on Medical Examination and Treatment No. 15/2023/QH15. January 9, 2023. Effective January 1, 2024, as amended where applicable.
Government of Viet Nam. Decree No. 96/2023/ND-CP, Detailing Certain Provisions of the Law on Medical Examination and Treatment. December 30, 2023, as amended where applicable.
Ministry of Health of Viet Nam. Circular No. 01/2013/TT-BYT, Providing Guidance on Laboratory Quality Management in Healthcare Facilities. January 11, 2013, as amended, including by Circular No. 25/2026/TT-BYT.
National Assembly of Viet Nam. Law on Personal Data Protection No. 91/2025/QH15. Effective January 1, 2026.
Government of Viet Nam. Decree No. 356/2025/ND-CP, Detailing Certain Provisions and Implementation Measures of the Law on Personal Data Protection. December 31, 2025. Effective January 1, 2026.
Professional Scope and Disclaimer
This article is published by Diagnostic Excellence Vietnam (DxEx.vn), a professional initiative dedicated to advancing diagnostic quality, safety, and reliability in Viet Nam through evidence-informed knowledge sharing, risk management, measurement, and quality improvement.
The content is intended for general professional education and discussion. It does not constitute patient-specific medical advice, an individualized newborn screening or diagnostic protocol, interpretation of a particular laboratory result, a recommendation for treatment, a determination of professional or technical error, an accreditation assessment, certification, or legal advice.
The discussion focuses on newborn screening using dried blood spot specimens. It does not provide detailed guidance on newborn hearing screening, screening for critical congenital heart disease, prenatal screening, or disease-specific treatment.
Screening methods, decision thresholds, additional specimen collection, confirmatory investigations, and clinical response times must be determined according to the condition involved, appropriately validated or verified analytical methods, applicable professional guidance, authorized service capabilities, and the infant's clinical circumstances.
A high-risk screening result does not necessarily establish that the newborn has the suspected disorder. Conversely, an in-range screening result does not exclude every disease and must not replace appropriate clinical assessment when concerning symptoms or findings develop.
References to international guidelines, CLSI standards, laboratory quality frameworks, and professional recommendations do not imply that these materials are automatically legally binding on every healthcare facility in Viet Nam.
Patient-specific decisions concerning newborn screening, diagnostic confirmation, urgent assessment, treatment, and follow-up must be made by appropriately qualified and authorized healthcare professionals in accordance with applicable Vietnamese law, relevant professional standards, and the patient's clinical circumstances.
Diagnostic Excellence Vietnam does not provide newborn screening, clinical diagnosis, or treatment services through this educational publication.
